A Review on Melatonin’s Effects in Cancer: Potential Mechanisms

Hanikoğlu, Aysegul; Kucuksayan, Ertan; Akduman, Rana Cagla; Özben, Tomris

doi:10.2174/1871520617666171121120223

Cited by 8 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TGF-β is one of the most potent immune suppressive cytokines, and CAFs are one of the main cells for the release of TGF-β. Since melatonin has been proven to suppress the expression level of TGF-β [ 68 ], it is reasonable to speculate that suppressing TGF-β secretion and weakening activities of CAFs are among the underlying mechanisms for the anticancer effects of melatonin.…”

Section: Anticancer Effect Of Melatoninmentioning

confidence: 99%

Use of Melatonin in Cancer Treatment: Where Are We?

Wang

Choi

2022

IJMS

View full text Add to dashboard Cite

Cancer represents a large group of diseases accounting for nearly 10 million deaths each year. Various treatment strategies, including surgical resection combined with chemotherapy, radiotherapy, and immunotherapy, have been applied for cancer treatment. However, the outcomes remain largely unsatisfying. Melatonin, as an endogenous hormone, is associated with the circadian rhythm moderation. Many physiological functions of melatonin besides sleep–wake cycle control have been identified, such as antioxidant, immunomodulation, and anti-inflammation. In recent years, an increasing number of studies have described the anticancer effects of melatonin. This has drawn our attention to the potential usage of melatonin for cancer treatment in the clinical setting, although huge obstacles still exist before its wide clinical administration is accepted. The exact mechanisms behind its anticancer effects remain unclear, and the specific characters impede its in vivo investigation. In this review, we will summarize the latest advances in melatonin studies, including its chemical properties, the possible mechanisms for its anticancer effects, and the ongoing clinical trails. Importantly, challenges for the clinical application of melatonin will be discussed, accompanied with our perspectives on its future development. Finally, obstacles and perspectives of using melatonin for cancer treatment will be proposed. The present article will provide a comprehensive foundation for applying melatonin as a preventive and therapeutic agent for cancer treatment.

show abstract

Section: Anticancer Effect Of Melatoninmentioning

confidence: 99%

Use of Melatonin in Cancer Treatment: Where Are We?

Wang

Choi

2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Melatonin, a natural neurohormone predominantly synthesized by the pineal gland, play an important role in both the synchronization and regulation of the sleep-wake cycle as well as circadian rhythms (4). In addition to its chronobiotic roles, melatonin possesses complex and different immunomodulatory and oncostatic abilities (5)(6)(7). Moreover, changed circadian levels of melatonin, especially a decrease in peak endogenous production, have been shown in relation to diverse cancers (8-10), cognitive impairment and healthy ageing (11,12).…”

Section: Introductionmentioning

confidence: 99%

The Effects of Melatonin Intake on Biomarkers of Inflammation and Oxidative Stress in Subjects with Breast Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial

Hashemi

Mousavi

Manouchehri-Ardakani

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: To our knowledge, data on the effects of melatonin supplementation on biomarkers of inflammation and oxidative stress in subjects with breast cancer are scarce. This research was done to assess the effects of melatonin supplementation on biomarkers of inflammation and oxidative stress in subjects with breast cancer. Methods: This randomized double-blind, placebo-controlled trial was conducted on 40 subjects diagnosed with breast cancer aged >25 years old. Subjects were randomly assigned into two groups to take either melatonin (n=20) or placebo (n=20) for 24 weeks. Inflammation and oxidative stress biomarkers were quantified at baseline and after the 24-week intervention. Results: After the 24-week intervention, compared with the placebo, melatonin supplementation significantly increased plasma total antioxidant capacity (TAC) (+21.3±26.2 vs. -6.3±34.5 mmol/L, P=0.007), and decreased plasma malondialdehyde (MDA) concentrations (-0.2±0.3 vs. +0.1±0.2 µmol/L, P=0.002). We did not observe any significant effect of melatonin supplementation on other biomarkers of oxidative stress. Conclusions: Overall, melatonin intake for 24 weeks in patients with breast cancer had beneficial effects on TAC and MDA levels, but did not affect other biomarkers of oxidative stress.

show abstract

“…8 Oxidative stress plays an important role in many diseases. [9][10][11][12][13][14][15][16] Similar to other inflammatory diseases, oxidative stress is associated with MS playing an important role in the pathogenesis of MS. 17 Unfortunately, a test in blood and body fluids is not available for the early diagnosis of MS and to follow and assess the course of the disease. Specific biomarkers for the diagnosis and prognosis of MS are currently under investigation, but unfortunately, they are not yet available.…”

Section: Introductionmentioning

confidence: 99%

“…In recent studies, it has been shown that in neurodegenerative diseases, these molecules regulate oxidative stress and the synthesis of many antioxidant molecules might increase in response to oxidative stress 8 . Oxidative stress plays an important role in many diseases 9‐16 . Similar to other inflammatory diseases, oxidative stress is associated with MS playing an important role in the pathogenesis of MS 17 .…”

Section: Introductionmentioning

confidence: 99%

Plasma thiol/disulphide homeostasis changes in patients with relapsing‐remitting multiple sclerosis

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background: Multiple sclerosis (MS) is a neuroinflammatory disease and inflammation and oxidative stress play important roles in its pathology. Thiol/disulphide homeostasis (TDH) is a special oxidative stress biomarker that has been found to be affected in several disorders including MS. There is no study demonstrating the effects of attack status of the relapsing-remitting multiple sclerosis (RRMS) patients on TDH levels. Our aim was to determine TDH levels in three different periods of RRMS patients and healthy individuals. Methods:The study was carried out in 29 patients with RRMS without a prior attack in the last twelve months (MS Control), 21 RRMS patients having a clinical acute attack within the last week (MS relapse), 12 of 21 MS relapse patients one month after the onset of attack and following 1000 mg methylprednisolone for 7 days (MS Remission) and 30 age-and sex-matched healthy individuals. TDH status was determined using an automated spectrophotometric analysis method. TDH levels in all patient groups and control subjects were compared with each other. Results:The lowest native thiol, total thiol levels and native thiol/total thiol ratio were found in the MS relapse patients in comparison to the MS control, MS remission groups and healthy controls. In contrast, disulphide levels, disulphide/native thiol and disulphide/total thiol ratios were highest in the MS relapse group compared to the other patient groups and healthy subjects. Conclusion:Our findings indicate that increased oxidative stress in RRMS patients is reflected with decreased native and total thiol and increased disulphide levels. Since the formation of disulphide bonds is reversible, the progression of RRMS involving abnormal TDH may be controlled, converting disulphides to thiols. So, we suggest determining the dynamic TDH status as a novel and special biomarker in the diagnosis and prognosis of the RRMS patients. What's known• Multiple sclerosis (MS) is a neuroinflammatory disease and inflammation and oxidative stress play important roles in its pathology.• Like other inflammatory diseases, oxidative stress is associated with MS playing an important role in the pathogenesis of MS.

show abstract

A Review on Melatonin’s Effects in Cancer: Potential Mechanisms

Cited by 8 publications

References 0 publications

Use of Melatonin in Cancer Treatment: Where Are We?

Use of Melatonin in Cancer Treatment: Where Are We?

The Effects of Melatonin Intake on Biomarkers of Inflammation and Oxidative Stress in Subjects with Breast Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial

Plasma thiol/disulphide homeostasis changes in patients with relapsing‐remitting multiple sclerosis

Contact Info

Product

Resources

About